{
  "VL_BX_19_4.raw": {
    "Source Name": [
      "VL_BX_19"
    ],
    "Assay Name": [
      "VL_BX_19_4"
    ],
    "Raw Data File": [
      "VL_BX_19_4.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "4"
    ]
  },
  "VL_BX_13bis_4.raw": {
    "Source Name": [
      "VL_BX_13bis"
    ],
    "Assay Name": [
      "VL_BX_13bis_4"
    ],
    "Raw Data File": [
      "VL_BX_13bis_4.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "4"
    ]
  },
  "VL_BX_21_3.raw": {
    "Source Name": [
      "VL_BX_21"
    ],
    "Assay Name": [
      "VL_BX_21_3"
    ],
    "Raw Data File": [
      "VL_BX_21_3.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "3"
    ]
  },
  "VL_BX_35_4.raw": {
    "Source Name": [
      "VL_BX_35"
    ],
    "Assay Name": [
      "VL_BX_35_4"
    ],
    "Raw Data File": [
      "VL_BX_35_4.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "4"
    ]
  },
  "VL_BX_29ter_3.raw": {
    "Source Name": [
      "VL_BX_29ter"
    ],
    "Assay Name": [
      "VL_BX_29ter_3"
    ],
    "Raw Data File": [
      "VL_BX_29ter_3.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "3"
    ]
  },
  "VL_BX_36qua_4.raw": {
    "Source Name": [
      "VL_BX_36qua"
    ],
    "Assay Name": [
      "VL_BX_36qua_4"
    ],
    "Raw Data File": [
      "VL_BX_36qua_4.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "4"
    ]
  },
  "VL_BX_28qua_1.raw": {
    "Source Name": [
      "VL_BX_28qua"
    ],
    "Assay Name": [
      "VL_BX_28qua_1"
    ],
    "Raw Data File": [
      "VL_BX_28qua_1.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "1"
    ]
  },
  "VL_BX_26B_4.raw": {
    "Source Name": [
      "VL_BX_26B"
    ],
    "Assay Name": [
      "VL_BX_26B_4"
    ],
    "Raw Data File": [
      "VL_BX_26B_4.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "4"
    ]
  },
  "VL_BX_3A_4.raw": {
    "Source Name": [
      "VL_BX_3A"
    ],
    "Assay Name": [
      "VL_BX_3A_4"
    ],
    "Raw Data File": [
      "VL_BX_3A_4.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "4"
    ]
  },
  "VL_BX_9_3.raw": {
    "Source Name": [
      "VL_BX_9"
    ],
    "Assay Name": [
      "VL_BX_9_3"
    ],
    "Raw Data File": [
      "VL_BX_9_3.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "3"
    ]
  },
  "VL_BX_27ter_1.raw": {
    "Source Name": [
      "VL_BX_27ter"
    ],
    "Assay Name": [
      "VL_BX_27ter_1"
    ],
    "Raw Data File": [
      "VL_BX_27ter_1.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "1"
    ]
  },
  "VL_BX_3B_2.raw": {
    "Source Name": [
      "VL_BX_3B"
    ],
    "Assay Name": [
      "VL_BX_3B_2"
    ],
    "Raw Data File": [
      "VL_BX_3B_2.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "2"
    ]
  },
  "VL_BX_27_1.raw": {
    "Source Name": [
      "VL_BX_27"
    ],
    "Assay Name": [
      "VL_BX_27_1"
    ],
    "Raw Data File": [
      "VL_BX_27_1.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "1"
    ]
  },
  "VL_BX_31_1.raw": {
    "Source Name": [
      "VL_BX_31"
    ],
    "Assay Name": [
      "VL_BX_31_1"
    ],
    "Raw Data File": [
      "VL_BX_31_1.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "1"
    ]
  },
  "VL_BX_17_4.raw": {
    "Source Name": [
      "VL_BX_17"
    ],
    "Assay Name": [
      "VL_BX_17_4"
    ],
    "Raw Data File": [
      "VL_BX_17_4.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "4"
    ]
  },
  "VL_BX_26A_3.raw": {
    "Source Name": [
      "VL_BX_26A"
    ],
    "Assay Name": [
      "VL_BX_26A_3"
    ],
    "Raw Data File": [
      "VL_BX_26A_3.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "3"
    ]
  },
  "VL_BX_35ter_2.raw": {
    "Source Name": [
      "VL_BX_35ter"
    ],
    "Assay Name": [
      "VL_BX_35ter_2"
    ],
    "Raw Data File": [
      "VL_BX_35ter_2.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "2"
    ]
  },
  "VL_BX_12bis_2.raw": {
    "Source Name": [
      "VL_BX_12bis"
    ],
    "Assay Name": [
      "VL_BX_12bis_2"
    ],
    "Raw Data File": [
      "VL_BX_12bis_2.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "2"
    ]
  },
  "VL_BX_10ter_2.raw": {
    "Source Name": [
      "VL_BX_10ter"
    ],
    "Assay Name": [
      "VL_BX_10ter_2"
    ],
    "Raw Data File": [
      "VL_BX_10ter_2.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "2"
    ]
  },
  "VL_BX_2ter_4.raw": {
    "Source Name": [
      "VL_BX_2ter"
    ],
    "Assay Name": [
      "VL_BX_2ter_4"
    ],
    "Raw Data File": [
      "VL_BX_2ter_4.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "4"
    ]
  },
  "VL_BX_31_3.raw": {
    "Source Name": [
      "VL_BX_31"
    ],
    "Assay Name": [
      "VL_BX_31_3"
    ],
    "Raw Data File": [
      "VL_BX_31_3.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "3"
    ]
  },
  "VL_BX_26B_3.raw": {
    "Source Name": [
      "VL_BX_26B"
    ],
    "Assay Name": [
      "VL_BX_26B_3"
    ],
    "Raw Data File": [
      "VL_BX_26B_3.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "3"
    ]
  },
  "VL_BX_29_2.raw": {
    "Source Name": [
      "VL_BX_29"
    ],
    "Assay Name": [
      "VL_BX_29_2"
    ],
    "Raw Data File": [
      "VL_BX_29_2.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "2"
    ]
  },
  "VL_BX_27ter_4.raw": {
    "Source Name": [
      "VL_BX_27ter"
    ],
    "Assay Name": [
      "VL_BX_27ter_4"
    ],
    "Raw Data File": [
      "VL_BX_27ter_4.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "4"
    ]
  },
  "VL_BX_27ter_3.raw": {
    "Source Name": [
      "VL_BX_27ter"
    ],
    "Assay Name": [
      "VL_BX_27ter_3"
    ],
    "Raw Data File": [
      "VL_BX_27ter_3.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "3"
    ]
  },
  "VL_BX_18ter_3.raw": {
    "Source Name": [
      "VL_BX_18ter"
    ],
    "Assay Name": [
      "VL_BX_18ter_3"
    ],
    "Raw Data File": [
      "VL_BX_18ter_3.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "3"
    ]
  },
  "VL_BX_21ter_2.raw": {
    "Source Name": [
      "VL_BX_21ter"
    ],
    "Assay Name": [
      "VL_BX_21ter_2"
    ],
    "Raw Data File": [
      "VL_BX_21ter_2.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "2"
    ]
  },
  "VL_BX_36ter_2.raw": {
    "Source Name": [
      "VL_BX_36ter"
    ],
    "Assay Name": [
      "VL_BX_36ter_2"
    ],
    "Raw Data File": [
      "VL_BX_36ter_2.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "2"
    ]
  },
  "VL_BX_30_3.raw": {
    "Source Name": [
      "VL_BX_30"
    ],
    "Assay Name": [
      "VL_BX_30_3"
    ],
    "Raw Data File": [
      "VL_BX_30_3.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "3"
    ]
  },
  "VL_BX_6_1.raw": {
    "Source Name": [
      "VL_BX_6"
    ],
    "Assay Name": [
      "VL_BX_6_1"
    ],
    "Raw Data File": [
      "VL_BX_6_1.raw"
    ],
    "Characteristics[Organism]": [
      "Homo sapiens"
    ],
    "Characteristics[MaterialType]": [
      "formalin-fixed paraffin-embedded (FFPE) biopsies"
    ],
    "Characteristics[Specimen]": [
      "tumor tissues of initial biopsy"
    ],
    "Characteristics[CleavageAgent]": [
      "Trypsin Gold (Promega)"
    ],
    "Characteristics[ReductionReagent]": [
      "dithiothréitol"
    ],
    "Characteristics[AlkylationReagent]": [
      "50 mM iodoacetamide"
    ],
    "Characteristics[Disease]": [
      "locally advanced non-metastatic rectal cancer"
    ],
    "Characteristics[OrganismPart]": [
      "locally advanced rectal adenocarcinoma"
    ],
    "Characteristics[NumberOfSamples]": [
      "23 participants"
    ],
    "Comment[Instrument]": [
      "OrbiTrap QExactive mass spectrometer (Thermo Fisher Scientific Inc)",
      "Dionex Ultimate 3000 nanoHPLC system"
    ],
    "Comment[Separation]": [
      "PepMap C18 nanocolumn (75 µm × 50 cm)",
      "Acclaim PepMap100 C18 column (0.3 mm id × 5 mm)"
    ],
    "Comment[FlowRateChromatogram]": [
      "constant flow of 4 µL/min",
      "constant flow of 200 nL/min"
    ],
    "Comment[GradientTime]": [
      "linear gradient of 5–35% solvent B over 240 min"
    ],
    "Comment[AcquisitionMethod]": [
      "The ten most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision induced dissociation (normalized collision energy 35% and resolution of 17,500) after the accumulation of 50,000 ions."
    ],
    "Comment[FragmentationMethod]": [
      "collision induced dissociation"
    ],
    "Comment[CollisionEnergy]": [
      "normalized collision energy 35%"
    ],
    "Comment[MS2MassAnalyzer]": [
      "acquired in the Orbitrap"
    ],
    "Comment[IonizationType]": [
      "EasySpray source"
    ],
    "Comment[FractionationMethod]": [
      "In-gel separation and tryptic digestion"
    ],
    "Comment[NumberOfFractions]": [
      "Each lane was divided into four gel slices."
    ],
    "Comment[NumberOfMissedCleavages]": [
      "2 miscleavages allowed"
    ],
    "Comment[PrecursorMassTolerance]": [
      "mass tolerance of 7 ppm for precursor ions"
    ],
    "Comment[FragmentMassTolerance]": [
      "20 ppm for fragment ions"
    ],
    "Comment[FractionIdentifier]": [
      "1"
    ]
  }
}